Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
about
Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.The new macrolides. Azithromycin and clarithromycin.Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection.Pharmacokinetics of a clarithromycin suspension in infants and children.Penetration of clarithromycin into lung tissues from patients undergoing lung resectionEvaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model.Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patientsPostantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobesCommonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance studyComparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycinIntrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pyloriThe new macrolide antibiotics. Azithromycin and clarithromycin.Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles.Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections.Preincubation of Haemophilus influenzae with subinhibitory concentrations of macrolides: influence on human neutrophil chemiluminescence.Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance.Bacterial challenges and evolving antibacterial drug strategy.Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH.In vitro activity and in vivo efficacy of a new series of 9-deoxo-12-deoxy-9,12-epoxyerythromycin A derivatives.Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae.MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.Pharmacokinetic properties of clarithromycin: A comparison with erythromycin and azithromycin.Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniaeAbsolute bioavailability of clarithromycin after oral administration in humans.Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum.In vitro susceptibility of Mycobacterium kansasii to clarithromycin.Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses.Accumulation of clarithromycin in macrophages infected with Mycobacterium avium.Amoxycillin clavulanate: an assessment after 15 years of clinical application.More macrolides.In vitro activity of clarithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzae.Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Clarithromycin Study Group.Nationwide surveillance of antimicrobial resistance among Haemophilus influenzae and Streptococcus pneumoniae in intensive care units in Taiwan.Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid.Seventy-five years of research on protein binding - do we ever understand?Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis.Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication
P2860
Q33541485-636557BF-F70C-4C71-AC60-E5F1FDDCE552Q33607251-69F5C874-3300-46FB-B552-1E6AD0674F39Q33697060-AEE7DACC-B5EE-4CFC-86DF-49DD99FA10F7Q33745585-DEEB7D06-0CE8-492C-B2CE-BA2FB0952A69Q33753604-7F468E73-FC42-4F5A-8FED-F38D131F95E2Q33758174-11F702DF-7659-49D1-8B6F-CAAB4A6FBF3EQ33976830-BA1E32AE-6F72-4BB4-9CF5-ECCA2D67F59FQ33979017-275820EF-36D3-44F3-B3E0-80EA94AA1EABQ34437719-A8FE2F20-544C-4CBA-AD94-B4B4D09A15E3Q34737818-30687690-6C7E-4CE2-B803-C236BFFF962CQ35128288-17FBCF0D-12DB-4DD1-8408-CEB049B35F64Q35136913-3D7CD568-4645-41A6-8104-643407D74D9BQ35137399-8408E9AA-823D-4124-AEF1-39A6A81FA0CCQ35229425-65E1B4EF-DCCF-4C77-A0E4-E16C3292C961Q35466622-1BEC4B18-F01D-4099-98FB-E8DC78070AFFQ35627730-A90A43EA-9E40-468A-927A-12DC8F9F9A5EQ35814392-3D25B5A9-C8D1-4C82-8AB1-6DF0B57A42F2Q35897251-72BC580A-E94E-4533-AD01-8AF1471F2346Q35990358-BA655ACC-6E14-4F1B-8036-E1681A077723Q36544285-74053B53-7F7B-45E4-8E1F-FF970DB618E5Q36753797-CFD92DAA-DB87-42C5-984D-6DC133631047Q36754391-3AFA9027-1C1A-4D29-A1EA-B200A994E020Q37115080-52B55599-4008-49B6-8AC4-796E29A20F00Q37985906-5A679C94-73CE-4541-9EFC-90D0125ECE02Q39470774-949A5B2A-0EC1-4F47-B3E4-2F600B62E750Q39869470-3D7A9454-9918-4B9F-9249-87256D6ED8D9Q39870885-04B178D6-3771-411D-A005-814335798488Q39882632-48CB4F1D-7FF3-4C09-901A-63786F55E7E3Q40284512-5D785705-7314-4BB5-8A2D-F81AD8294DC8Q41499115-ED178ABC-A0D3-4F53-A084-7BC531B1CBE2Q41520020-848992A6-F05C-419A-A53F-ECCBAE9F683BQ43162758-02F266C3-4FC4-48AD-8F94-AB583B9755BEQ43601652-53E3BCCA-65A6-4881-9D12-576C8B20E20AQ44915723-16178B32-EAA1-4F2F-81C1-83347ACFB366Q46091408-7DBCF736-B7BC-46E1-BBBC-BF2DF5F6556CQ46703565-C686323D-5236-4509-9CC0-3432790F7911Q47381610-25CCF464-F9BD-48A3-A79F-6EB8E6ABE7B5Q54066788-9EA755BA-D983-4F76-B1DD-4310AC02DFBDQ58217061-9B255F1B-F370-40BD-B3E7-8463B7E2D5BD
P2860
Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Enhancement of the in vitro an ...... ts major metabolite in humans.
@ast
Enhancement of the in vitro an ...... ts major metabolite in humans.
@en
type
label
Enhancement of the in vitro an ...... ts major metabolite in humans.
@ast
Enhancement of the in vitro an ...... ts major metabolite in humans.
@en
prefLabel
Enhancement of the in vitro an ...... ts major metabolite in humans.
@ast
Enhancement of the in vitro an ...... ts major metabolite in humans.
@en
P2093
P2860
P356
P1476
Enhancement of the in vitro an ...... ts major metabolite in humans.
@en
P2093
P2860
P304
P356
10.1128/AAC.34.7.1407
P407
P577
1990-07-01T00:00:00Z